• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Alnylam's vutrisiran gets fast-track treatment at the FDA

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 14, 2020 at 09:52: AM
via FDA has put Alnylam’s RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis on its regulatory fast track. Alnylam secured the designation for the candidate, vutrisiran, ahead of the anticipated readout from a phase 3 trial early next year.

article source
 




Top Bottom
Back
Quote